title: Effect of antenatal steroid administration on the fetal biophysical profile.
abstract: OBJECTIVE
  Our objective was to determine whether antenatal steroid administration affects the biophysical profile score in fetuses.
  
  
  METHODS
  A prospective study was conducted in 84 fetuses between 28 and 34 weeks' menstrual age at risk of preterm delivery. Two intramuscular injections of 12 mg of betamethasone were given to the mother 24 hours apart. All fetuses underwent biophysical profile testing prior to and between 24 and 48 hours after steroid administration. Biophysical profiles (including nonstress tests) were evaluated by two maternal-fetal medicine specialists blinded to the timing of steroid administration. Neonatal outcome, including Apgar score, menstrual age at delivery, admission to and length of stay in the neonatal intensive care unit, and mortality, was analyzed in all subjects.
  
  
  RESULTS
  In 31 (37%; 95 confidence interval, 26.6-47.2%) of 84 cases, the biophysical profile score decreased at least 2 points after steroid administration. The most commonly affected variables were fetal breathing and the nonstress test. There was no significant difference in the neonatal outcome between the fetuses whose biophysical profile decreased and those whose did not.
  
  
  CONCLUSIONS
  Biophysical profile scores were decreased in more than one third of fetuses within 48 hours of antenatal steroid administration, but neonatal outcome was not affected. Knowledge of this occurrence could avoid incorrect decision making regarding fetal well-being.
authors.affiliation: North Shore University Hospital, 300 Community Drive, Manhasset, New York 11030, USA.
authors.forename: M K
authors.initials: MK
authors.lastname: Kelly
authors.forename: E P
authors.initials: EP
authors.lastname: Schneider
authors.forename: B M
authors.initials: BM
authors.lastname: Petrikovsky
authors.forename: M L
authors.initials: ML
authors.lastname: Lesser
mesh_terms: D000328:Adult; D000653:Amniotic Fluid / Q000000981:diagnostic imaging; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D016001:Confidence Intervals; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005316:Fetal Distress / Q000000981:diagnostic imaging* / Q000209:etiology*; D005324:Fetal Movement; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006340:Heart Rate, Fetal; D006801:Humans; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D007363:Intensive Care Units, Neonatal; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D016216:Ultrasonography, Prenatal
chemical_list: D005938:Glucocorticoids; D001623:Betamethasone